Rochelle Hanley
CIK 1614595 · Chief Medical Officer · last filed 2016-05-05
Rochelle Hanley is a Chief Medical Officer who has filed 3 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing shows the insider had shares withheld for taxes covering $13.9K of VKTX.W on May 5, 2016. Current disclosed insider exposure totals $2.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.71M
2
3
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX.W) Delisted | Chief Medical Officer | 160,836 | — | — | $0 | 1 | 2016-05-05 |
| VKTX | Chief Medical Officer | 91,547 | $29.65 | $2.71M | $0 | 2 | 2016-03-08 |
Recent Filings
3 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-05-05 | Viking Therapeutics, Inc. (VKTX.W) Delisted | Tax (F) | −10,595 | -$13.9K | EDGAR |
| 2016-03-08 | VKTX | Grant (A) | — | $0 | EDGAR |
| 2015-05-06 | VKTX | Mixed | −81,145 | $69.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.